Title
Early treatment with erythromycin of Campylobacter jejuni-associated dysentery in children
Date Issued
01 January 1986
Access level
metadata only access
Resource Type
journal article
Author(s)
Publisher(s)
Elsevier
Abstract
To evaluate the efficacy of early treatment with erythromycin on the duration of fecal excretion and of diarrhea associated with Campylobacter jejuni, 170 patients, age 3 to 60 months, were randomly assigned in a double-blind fashion to receive either erythromycin ethyl succinate or placebo immediately after being seen at Cayetano Heredia Hospital because of acute dysentery. The groups' pretreatment characteristics were comparable. Of the 30 patients with stools positive for C. jejuni, 12 were in the placebo group and 16 in the treatment group. After 2 days of treatment, none of the patients in the placebo group and 36% of those in the erythromycin group had normal stools (P<0.05). After 5 days of treatment, 50% of the patients in the placebo group and 93% of those in the erythromycin group had normal stools (P<0.02). Fecal excretion of the organism continued significantly longer in the placebo group (P<0.01). There were no treatment failures in the treatment group compared with five (42%) in the placebo group (P<0.01). Thus, early administration of erythromycin significantly reduced the duration of both diarrhea and fecal excretion of the organism in infants and children with acute dysentery associated with C. jejuni. © 1986 The C. V. Mosby Company.
Start page
355
End page
360
Volume
109
Issue
2
Language
English
OCDE Knowledge area
Pediatría
Tecnología médica de laboratorio (análisis de muestras, tecnologías para el diagnóstico)
Farmacología, Farmacia
Scopus EID
2-s2.0-0022508390
PubMed ID
Source
The Journal of Pediatrics
ISSN of the container
00223476
Sponsor(s)
Several authors have recommended erythromycin as the drug of choice in treating symptomatic Campylobacter jejuni infections, based on studies of in vitro susceptibility of the organism to antimicrobial agents ~3 and on uncontrolled clinical observations. 47 Recently published con- Presented in part at the 21st U.S.-Japan Cholera Conference, October 21-23, 1985. Supported by grants from Abbott Laboratories and Nestec Ltd., Vevey, Switzerland. Submitted for publication Nov. 18, 1985; accepted March 4, 1986. Reprint requests: R. Bradley Sack, M.D., The Johns Hopkins University School of Public Health, Department of International Health, Division of Geographic Medicine, 615 N. Wolfe St., Baltimore, MD 21205.
Sources of information:
Directorio de Producción Científica
Scopus